


Johnson & Johnson JNJ ★★ 21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

Price vs. Fair Value



Total Return % as of 20 Jan 2026. Last Close as of 20 Jan 2026. Fair Value as of 21 Jan 2026 20:53, UTC.

Contents

Analyst Note (21 Jan 2026)
Business Description
Business Strategy & Outlook (21 Jan 2026)
Bulls Say / Bears Say (21 Jan 2026)
Economic Moat (21 Jan 2026)
Fair Value and Profit Drivers (21 Jan 2026)
Risk and Uncertainty (24 Sep 2025)
Capital Allocation (21 Jan 2026)
Analyst Notes Archive
Financials
ESG Risk
Appendix
Research Methodology for Valuing Companies

Important Disclosure

The conduct of Morningstar's analysts is governed by Code of Ethics/Code of Conduct Policy, Personal Security Trading Policy (or an equivalent of), and Investment Research Policy. For information regarding conflicts of interest, please visit: <http://global.morningstar.com/equitydisclosures>.

The primary analyst covering this company does not own its stock.

¹The ESG Risk Rating Assessment is a representation of Sustainalytics' ESG Risk Rating.

Johnson & Johnson Earnings: A Steady 2025 and Improving 2026 Warrant a FVE Increase

Analyst Note Karen Andersen, CFA, Director, 21 Jan 2026

J&J reported 6% sales growth and 8.1% diluted adjusted EPS growth in 2025, with 2026 growth guidance of 6.7% for sales and 6.9% for diluted adjusted EPS at the midpoint.

Why it matters: The biopharma industry (including J&J) is grappling with patent expirations on key drugs, but we're impressed by J&J's ability to grow solidly despite the erosion of its immunology drug Stelara (a 620-basis-point headwind to 2025 sales) and to step up its 2026 growth outlook.

► Both Innovative Medicine and MedTech divisions had similar mid-single-digit growth rates in 2025, reflecting broad-based strength in areas from oncology (22% growth, led by Darzalex and Carvykti) to electrophysiology (16% growth) and adding support to the firm's outlook for 2026.


The bottom line: We're raising our fair value estimate for wide-moat J&J to \$182 from \$172, with the biggest adjustments to our oncology and immunology forecasts. For long-term investors, we think shares still incorporate too much of a premium for J&J's clearer near-term prospects.

- In oncology, we now see total sales around \$40 billion by 2030 (from \$25 billion today) as J&J continues to gain share and launch promising combinations in multiple myeloma, but also launches new treatments in other areas, like Inlexzo for bladder cancer.
- In immunology, we think Tremfya can grow to \$12 billion by 2030, and when combined with the upcoming potential launch of Icotyde (icotrokinra), new drugs more than counter further declines in

Johnson & Johnson JNJ ★★

21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

Sector	Industry
 Healthcare	Drug Manufacturers - General

Business Description

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Stelara.

Big picture: Our mid-single-digit growth outlook through 2030 and \$40 billion oncology sales forecast are still below management's forecast (double-digit growth by 2030, \$50 billion in oncology sales). We're watching for key data this year, like cardiovascular drug milvexian, to adjust our outlook.

Business Strategy & Outlook Karen Andersen, CFA, Director, 21 Jan 2026

Johnson & Johnson stands alone as a leader across major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat.

J&J holds a leadership role in diverse healthcare segments, including medical technologies and several pharmaceutical markets. Contributing close to two-thirds of total revenue, the Innovative Medicine division boasts several industry-leading drugs, including immunology drugs Stelara and Tremfya as well as cancer drugs Darzalex and Imbruvica. The MedTech group brings in one-third of sales, with the company holding strong positions in many areas, including electrophysiology, vision, and surgery markets. In 2023, J&J spun off its consumer division into a new stand-alone company, Kenvue, which leaves the remaining company more focused on drugs and devices. The upcoming orthopedics spin (expected in 2027) will leave J&J even more focused on higher-margin, higher-growth products.

The pharmaceutical segment recently launched several new blockbusters including CAR-T cell therapy Carvykti and depression drug Spravato, with bladder cancer therapy Inlexzo and oral immunology drug Icotyde poised to further support growth and counter patent expirations on older products. The company has also created new medical devices, including innovative contact lenses, minimally invasive surgical tools, and robotic instruments, and is launching several innovative cardiovascular devices that are supporting strong growth.

These multiple businesses generate substantial returns on invested capital, which look likely to remain in the midteens or approaching 20%, well above our estimated 7.2% cost of capital. Strong cash generation has enabled the firm to increase its dividend for over the past half century, and we expect this to continue. It also allows J&J to take advantage of acquisitions to opportunistically support growth, like the 2025 acquisition of Intra-Cellular (neurology drug Caplyta). Diverse operating segments coupled with expected new products insulate J&J more from patent losses relative to other Big Pharma firms.

Bulls Say Karen Andersen, CFA, Director, 21 Jan 2026

- J&J's strong position in oncology (Darzalex and Carvykti) and next-generation immunology product Tremfya (following Stelara) create a foundation of innovative drugs.
- Diverse healthcare segments help insulate J&J from downturns in the overall economy, offering a defensive growth opportunity with a steady and likely growing dividend.

Johnson & Johnson JNJ ★★ 21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	7 Jan 2026 06:00, UTC

Competitors

	Johnson & Johnson JNJ	AbbVie Inc ABBV	Merck & Co Inc MRK	Novartis AG Registered Shares NOVN
Economic Moat	Wide	Wide	Wide	Wide
Currency	USD	USD	USD	CHF
Fair Value	182.00 21 Jan 2026 20:53, UTC	184.00 31 Jan 2025 18:07, UTC	111.00 4 Feb 2025 19:32, UTC	96.00 29 Oct 2025 11:12, UTC
1-Star Price	227.50	285.20	149.85	129.60
5-Star Price	145.60	110.40	77.70	67.20
Assessment	Overvalued 21 Jan 2026	Overvalued 20 Jan 2026	Fairly Valued 20 Jan 2026	Overvalued 21 Jan 2026
Morningstar Rating	★★ 21 Jan 2026 21:03, UTC	★★ 20 Jan 2026 22:55, UTC	★★★ 20 Jan 2026 22:40, UTC	★★ 21 Jan 2026 18:21, UTC
Analyst	Karen Andersen, Director	Karen Andersen, Director	Karen Andersen, Director	Jay Lee, Senior Equity Analyst
Capital Allocation	Standard	Standard	Standard	Standard
Price/Fair Value	1.20	1.16	0.99	1.19
Price/Sales	5.74	6.36	4.29	4.70
Price/Book	6.62	—	5.25	6.20
Price/Earning	26.56	57.51	14.09	16.04
Dividend Yield	2.36%	3.11%	3.00%	3.06%
Market Cap	525.73 Bil	378.29 Bil	271.66 Bil	219.39 Bil
52-Week Range	141.50—215.19	164.39—244.81	73.31—112.90	81.10—114.70
Investment Style	Large Value	Large Value	Large Value	Large Blend

- Several of J&J's key next-generation pipeline drugs are specialty drugs that tend to carry strong pricing power as well as lower regulatory hurdles for approval.

Bears Say Karen Andersen, CFA, Director, 21 Jan 2026

- J&J's late-stage drug pipeline could face significant competitive threats, as oncology and immunology remain popular areas for biopharma investment.
- Biosimilar competition to Stelara is rapidly eroding sales of the drug, putting pressure on the rest of the portfolio to compensate.
- J&J's orthopedics segment is struggling to maintain share against more focused players like Stryker and Zimmer Biomet.

Economic Moat Karen Andersen, CFA, Director, 21 Jan 2026

We believe Johnson & Johnson carries one of the widest moats in the healthcare sector, supported by

Johnson & Johnson

JNJ★★

21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

intellectual property in the drug group and intellectual property and (to a lesser extent) switching costs in the device segment. The company's diverse revenue base, strong pipeline, and robust cash flow generation create a very wide economic moat. An extensive salesforce makes J&J a powerful candidate for a smaller biotechnology company looking to partner on a new drug, which strengthens J&J's ability to bring new products to market.

Johnson & Johnson's diverse operations are a major pillar supporting the wide moat. The company holds a leadership role in a number of drug and device markets. The company is not overly dependent on one particular operating segment; the pharmaceutical business and medical device group represent close to 65% and 35% of total sales, respectively. Additionally, within each segment, no one product dominates sales, and the largest drug in sales, Darzalex, was only 15% of total sales in 2025.

Johnson & Johnson's R&D efforts support its robust revenue base. In pharmaceuticals, the firm recently launched several new blockbusters, which should allow it to escape largely unscathed from its biggest patent headwinds, led by immunology drug Stelara (12% of 2024 sales). Its efforts in medical devices, including robotics and digital data, should help maintain leadership in several medical device areas as well as support strong pricing power. Switching costs remain high with several of the device products. For example, physicians switching vendors for hip and knee devices could take weeks if not months to learn the new products, which keeps physicians tied to the company's products.

We think the firm does face environmental, social, and governance risks, particularly related to potential US drug price-related policy reform (38% of 2024 sales were generated by prescription drugs in the US) to increase access by lowering drug prices. Ongoing product governance issues, including litigation related to side effects and patents, also weigh on the company. While we have factored these threats into our analysis, we don't see them as material to the company's moat rating.

Fair Value and Profit Drivers Karen Andersen, CFA, Director, 21 Jan 2026

We are raising our fair value estimate to \$182 per share from \$172, following strong fourth-quarter sales across several J&J business areas and a solid outlook for 2026 and beyond.

With broad strength in J&J's innovative medicine and medtech segments, we expect mid-single-digit top- and bottom-line growth over the next five years, despite headwinds from moving past its biggest patent cliff beginning in 2025 (the immunology drug Stelara, 12% of 2024 sales).

In the drug unit, strong innovative new drug launches are helping to offset increasing patent pressures. In immunology, J&J looks well-positioned to mitigate the patent loss for Stelara with recently launched drugs that hold the potential to expand in approved indications and gain traction in new indications. We view Tremfya as well-positioned for growth, leading to peak annual sales of \$12 billion in 2030. While the drug was approved in 2017 for moderate to severe psoriasis, we expect follow-up data as well as

Johnson & Johnson JNJ ★★

21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

new gastrointestinal indications to drive the robust sales.

In oncology, J&J continues to report strong data, suggesting increased potential for several of its drugs. Adding to the firm's strong entrenchment in multiple myeloma with Darzalex, we expect CAR-T drug Carvykti and bispecific antibodies Tecvayli and Talvey to post solid gains. Also, the firm's Rybrevant/Lazcluze combination targeting EGFR-mutated lung cancer looks increasingly well-positioned to develop into blockbuster sales in 2026.

We expect annual adjusted earnings per share growth to average more than 6% during the next five years, as strong growth in new pipeline drugs should offset some patent losses in the pharmaceutical division. We expect fairly flat operating margins over the next several years as cost-containment efforts across the firm help offset margin pressure from the loss of patent protection on several high-margin drugs, including the immunology drug Stelara.

Risk and Uncertainty Karen Andersen, CFA, Director, 24 Sep 2025

Johnson & Johnson needs to overcome several legal roadblocks, including remaining litigation surrounding several products, including talcum powder. The litigation can cause major settlements and could damage its sterling reputation. Over the longer term, the company faces typical healthcare risks such as reduced pricing power from both governments and pharmacy benefit managers, regulatory delays, and nonapprovals as well as increasingly aggressive generic competition for small-molecule drugs and biologics. However, given such a wide portfolio of products, we assign the firm a Morningstar Uncertainty Rating of Low.

Our rating for the company is not materially affected by ESG risks. We see access to basic services (tied to drug pricing) as the biggest ESG risk that the firm needs to manage. J&J generates close to one-third of total sales from US prescription drug sales (slightly lower relative to peers), and additional major pricing reforms could weigh on its sales and margins.

We assume a more than 50% probability of J&J seeing future costs related to product governance ESG risks (such as off-label marketing or litigation related to side effects) and model base-case annual legal costs at 3% of non-GAAP net income (on the high end relative to peers as J&J's product portfolio is more prone to possible litigation).

Capital Allocation Karen Andersen, CFA, Director, 21 Jan 2026

We assign Johnson & Johnson a Standard Morningstar Capital Allocation Rating. The rating reflects our belief that J&J possesses a sound balance sheet, a reasonable record of investments, and largely fair shareholder distributions.

We believe J&J holds a sound balance sheet with low levels of risk regarding the size of the debt carried, the business cyclicalities facing the firm, and the debt maturity outlook. While an argument could be

Johnson & Johnson JNJ ★★

21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

made to increase the leverage of the balance sheet to be more active in investing, we believe J&J, along with the majority of firms in the large-cap biopharma industry, should hold ample balance sheet strength to support opportunistic acquisitions as dynamic scientific data emerges that might require relatively quick investment action. Also, a strong balance sheet helps biopharma firms through most product litigation challenges with minimal concern from the market.

Turning to investments, we believe J&J is operating at a reasonable level. The company tends to spend over 20% of sales on R&D for the drug business (above the industry average of high teens) and close to 9% of sales on R&D for the device business (close to the industry average of 8%-9%). The company has shown high productivity with strong execution in drug pipeline development. The strong productivity in creating the next generation of drugs has yielded enough new drugs to help mitigate patent losses. The strong productivity in innovative new drugs (largely targeting areas of unmet medical need, especially in oncology and immunology) also helps fortify the firm's wide moat and expand returns on invested capital. Innovation in the device segment appears to have largely lagged peers in the orthopedic space, especially around robotic developments, although the planned spinoff of this business in 2027 could help J&J focus more on areas where it has an innovative edge.

On the acquisition side, J&J has executed reasonably well. The acquisition of Actelion for close to \$30 billion brought in an important rare-disease franchise where pricing power looks strong. However, we are skeptical that the acquisition created much value, given the high price paid. The \$6 billion acquisition of Momenta Pharmaceuticals also looked fairly expensive, but value creation will depend on the success of the recently approved autoimmune disease drug Imaavy. The 2025 acquisition of Intra-Cellular and neuroscience drug Caplyta is also a great fit with the firm's growing neuroscience portfolio, and the \$14.6 billion price looks fair. On the medical device side, the acquisitions of Abiomed and Shockwave look like reasonable uses of cash that provide J&J with innovative products that it can leverage through its strong distribution channels.

We view J&J's dividends and share repurchases as about right. J&J has a very long history of consistently raising its dividend, giving investors high confidence in the business. Further, the firm is able to fund strong internal investments while supporting the dividend and some moderate and largely well-timed share repurchases over the past several years.

Joaquin Duato took over the CEO spot from Alex Gorsky in early 2022. Given Duato's 30-plus years at J&J, including the recently successful strategy work in the drug and consumer divisions, we believe Duato will continue the industry-leading innovative strategy that was pursued under Gorsky. We expect continued steady growth based on the diverse group of product lines. However, we don't expect the extra-long duration typical of a J&J CEO, as Duato was 59 years old when he took on the top spot. With strong leaders supporting Duato, including Jennifer Taubert (head of the innovative medicine unit) and Tim Schmid (head of the medtech unit) at the two largest business segments and Joe Wolk as CFO, Duato has a strong support structure for current business operations as well as leading internal

Johnson & Johnson JNJ ★★ 21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

candidates for the eventual next CEO succession.

Analyst Notes Archive

Johnson & Johnson Earnings: Surpassing Expectations Across the Board Karen Andersen, CFA,Director,16 Jul 2025

In the second quarter, Johnson & Johnson saw 4.6% constant-currency sales growth and a 1.8% decline in adjusted diluted EPS. Management raised its 2025 guidance for constant-currency revenue growth (to 4.8% at the midpoint from 3.8%) and adjusted diluted EPS growth (to 8.7% from 6.2%). Why it matters: Johnson & Johnson is facing a steep patent cliff this year due to biosimilar competition to immunology blockbuster Stelara, and the company's strong growth despite this headwind is a testament to its diversified business and foundation of differentiated treatments. Within the innovative medicine segment (3.8% constant currency growth), strength in neurology (Spravato, Carvykti), oncology (Darzalex, Carvykti), and immunology (Tremfya) was broadly above our expectations and driven by demand, which we think is encouraging for long-term growth. In medtech (6.1% growth), double-digit growth in cardiology with multiple launches across electrophysiology and recent Abiomed and Shockwave acquisitions was also above our expectations and countered a slight decline in orthopedics. The bottom line: We've raised our fair value estimate for wide-moat J&J to \$172 per share from \$164 after slightly increasing our growth trajectories for several drugs and devices that have strong long-term outlooks. On tariffs, J&J's exposure has lessened due to reduced China medtech tariffs. While we continue to watch for updates on potential pharmaceutical tariffs, we think J&J is in a good position, with most US-bound products already made in the US and a plan for complete coverage within five years. Coming up: We expect J&J's pipeline to begin to significantly contribute to growth by next year, with new products like Imaavy (approved in myasthenia gravis) and upcoming expected approvals for TAR-200 (bladder cancer) and Caplyta (new indication in major depressive disorder).

Biopharma Industry: Latest Executive Order Threatens Broad Cut to US Drug Prices Karen Andersen, CFA,Director,12 May 2025

President Trump released an executive order on May 12 calling for a 30-day negotiation period between the Department of Health and Human Services and the biopharma industry, with the threat of a rule from the Centers for Medicare and Medicaid Services to lower US drug prices if no deal is reached. Why it matters: The president's goal of bringing US drug prices more in line with pricing in other developed countries is among the more feared potential policy changes in the biopharma industry, although we have generally seen sweeping changes as a low-probability scenario. While discounts in the US and other markets make it quite difficult to get a clear comparison of net prices in various markets, we've estimated that US prices are on average roughly double those in major international markets. We have estimated that bringing US prices in line with European prices across US channels (public and private)

Johnson & Johnson JNJ ★★ 21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

would result in a 24% hit to US drug revenue, and with most firms bringing in about half of their revenue from the US, a worst-case scenario would mean a low-double-digit top-line hit. The bottom line: We're maintaining our fair value estimates in this largely wide-moat industry. While a worst-case scenario would lower our fair value estimates, shares rose on Trump's announcement, as we think investors are encouraged by the vagueness of the order and the significant room for negotiations. We think a likely final focus for price cuts could be Medicare drug spending in hospitals, which represents 10% of the US drug market, limiting exposure relative to broader Medicare (30%) or all government programs (closer to 50%). Rulemaking is a hard way to make large changes stick. Historically, Congress has been the source of major policy changes in the industry. Efforts to include Medicaid price benchmarking in the emerging reconciliation bill appear to have failed, which likely limit Trump's scope for action.

Biopharma Industry: Trump's Executive Order Could Help Innovation, but Range of Scenarios Still Open Karen Andersen, CFA, Director, 16 Apr 2025

President Donald Trump issued an executive order on April 15 listing several potential policy changes aimed at lowering US drug prices. Why it matters: Biopharma has been holding its breath as it awaits Trump's plans for reducing drug costs, with a range of possible policy changes that could help or hinder innovation. As a worst-case scenario, international price benchmarks could significantly lower US drug pricing and reduce economic incentives for innovative drug development globally. On a more positive note, correcting the "pill penalty" that only gives small molecule drugs nine years of protection from Medicare negotiation (biologics get 13) could encourage innovation regardless of treatment modality. The bottom line: We're not making any changes to our valuations or uncertainty ratings as a result of Trump's recent executive order, which was light on details and could be construed as a positive or negative for the industry. Trump wants US Department of Health and Human Services Secretary Robert F. Kennedy Jr. to work with Congress to correct the pill penalty, although this relies on Congressional action and does not specify how long the protection period should be. Another goal is for RFK to begin a new Medicare payment model to lower drug prices within one year, which could revive Trump's international price benchmarking model that was finalized under Trump in 2020 but halted by President Joe Biden in 2022. Big picture: We think the biopharma industry looks undervalued, as innovation and a promising mergers and acquisitions environment support long-term pricing power and help counter potential near-term tariff pressure, long-term rising tax rates as US manufacturing increases, and likely approval delays.

Johnson & Johnson Earnings: Maintaining Valuation on Solid Innovation and Manageable Tariff Headwind Karen Andersen, CFA, Director, 15 Apr 2025

J&J reported 2.4% first-quarter sales growth (2.3% in innovative medicine, 2.5% in medtech) and 2.2% adjusted EPS growth in the first quarter. Management raised reported sales growth guidance for 2025

Johnson & Johnson JNJ ★★

21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

to 3.1% at the midpoint but maintained adjusted EPS guidance for 6.2% growth at the midpoint. Why it matters: Investors were concerned about how severely the headwinds from Stelara biosimilars and the Medicare Part D redesign would hit Johnson & Johnson's financials, as well as the potential impact of tariffs, but the firm looks on track to grow as expected this year. The acquisition of neuroscience drug Caplyta and foreign exchange fluctuations account for the sales guidance increase, as adjusted operational sales growth was maintained at 2.5% at the midpoint. J&J expects a \$400 million impact this year from confirmed tariffs, mostly on its medtech business, with the biggest factor being China retaliatory tariffs for products made in the US and shipped to China. Management noted that existing contracts limit price leverage to mitigate the effects. The bottom line: We're maintaining our \$164 fair value estimate, as we have slightly increased our sales forecasts for key blood cancer product Carvykti and immunology drug icotrokinra, but we have also added tariff pressure on medtech and increased our assumed long-term tax rate for J&J. Strong sales for Carvykti, as well as recent promising data for icotrokinra in psoriasis, should help nudge J&J into mid-single-digit top-line growth territory over the next few years. As we discussed in our recent notes on tariffs, we think increased US manufacturing and potential tax policy changes could bring tax rates for biopharma firms closer to the 21% US corporate tax rate level over the next several years, from roughly 15% for the group currently.

Biopharma Industry: We Anticipate Tariffs to Bring Short-Term Margin Pressure; No Valuation Changes

Karen Andersen, CFA, Director, 9 Apr 2025

President Trump has announced that "major" pharmaceutical product tariffs are likely to be revealed soon, but at the same time, paused broader tariffs for most trade partners for 90 days to allow time for negotiations. Why it matters: The biopharma industry has largely been exempt from tariffs (except for 20% tariffs on imports to the US from China, implemented in March). The industry continues to brace for a potential pharma-specific announcement, which could have implications for global manufacturing strategies. The rumored 25% tariff could be applied to products manufactured in Europe and imported into the US. While there might be some flexibility to move toward a more domestic manufacturing strategy, avoiding tariffs completely would require new facilities that take several years to build. Both US and Europe-based firms have significant European manufacturing exposure due to tax advantages (US firms), home country manufacturing (Europe firms), and other reasons, including lower production costs and lower exposure to currency fluctuations. The bottom line: We are not changing our biopharma uncertainty ratings or fair value estimates, as we think the direct impact from tariffs on earnings is likely to be limited in scope. Moreover, the indirect impact from a potential recession should also be limited given the noncyclical nature of drug spending. We assume pharmaceutical tariffs are enacted but do not last after 2026 due to political pressure from midterm elections. In this scenario, we think biopharma is unlikely to wholesale rethink its manufacturing footprint, apart from incremental US capacity additions. Using a non-GAAP industry average margin analysis of the short-run tariff impact, a 25% tariff would only amount to a 2-percentage-point operating margin headwind in the worst case, or

Johnson & Johnson

JNJ★★

21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	 Wide	 Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

a 6% headwind to operating profits, using an industry average 32% operating profit margin.

Biopharma Industry: Exempt From Global 10% Tariff, but We Still See Margin and Tax Rate Risks


Karen Andersen, CFA,Director,3 Apr 2025

On April 2, President Donald Trump announced a 10% tariff on imports from all countries, effective on April 5. However, pharmaceuticals appear to be among the exemptions listed in the full executive order, as part of Annex II. Why it matters: The biopharma industry has been sheltered from tariffs for decades, including during the first Trump administration, but investors had been concerned about potential global tariffs, as the industry has significant manufacturing in European countries like Ireland, Germany, and Switzerland. With roughly \$200 billion in pharmaceutical imports in 2024, a 10% tariff could amount to a \$20 billion headwind across the industry, with the biggest firms seeing potential annual tariffs as high as \$1 billion. Previously implemented tariffs on pharmaceutical imports from China (raised from 10% in February to 20% in March) appear manageable for branded biopharma, due to limited manufacturing in China, and pharmaceuticals are generally exempt from Mexico and Canada tariffs (25%, March 2025). The bottom line: We think a future global pharmaceutical tariff is still a risk and could pressure gross margins and increase long-term tax rates. However, we expect firms to be able to adapt their manufacturing, and nearly all large-cap biopharma firms continue to hold wide economic moats. On margins, we could see near-term pressure from tariffs and long-term pressure from additional investment in US manufacturing facilities, which are not likely to receive approval for several years, even assuming US Food and Drug Administration inspections stay on track following staff reductions. With increased US manufacturing, we expect tax rates could begin to rise closer to the current 21% US corporate tax rate, a level we assume will be maintained as Trump aims to extend his tax cuts via the reconciliation process in the Republican-controlled Congress. ■■

Johnson & Johnson JNJ ★★ 21 Jan 2026 21:03, UTC


Competitors Price vs. Fair Value

AbbVie Inc ABBV



Total Return % as of 20 Jan 2026. Last Close as of 20 Jan 2026. Fair Value as of 31 Jan 2025 18:07, UTC.

Merck & Co Inc MRK



Total Return % as of 20 Jan 2026. Last Close as of 20 Jan 2026. Fair Value as of 4 Feb 2025 19:32, UTC.

Johnson & Johnson


JNJ★★

21 Jan 2026 21:03, UTC

Competitors Price vs. Fair Value

Novartis AG Registered Shares

NOVN



Total Return % as of 21 Jan 2026. Last Close as of 21 Jan 2026. Fair Value as of 29 Oct 2025 11:12, UTC.

Johnson & Johnson ★★ 21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	 Wide	 Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

Morningstar Valuation Model Summary

Financials as of 21 Jan 2026

Fiscal Year, ends 31 Dec	Actual			Forecast				
	2022	2023	2024	2025	2026	2027	2028	2029
Revenue (USD Mil)	79,990	85,159	88,821	94,195	100,262	103,471	108,914	113,977
Operating Income (USD Mil)	21,013	23,409	22,149	25,598	27,887	29,376	31,649	33,749
EBITDA (USD Mil)	26,115	22,083	23,409	40,324	37,482	38,589	40,602	42,480
Adjusted EBITDA (USD Mil)	26,115	22,083	23,409	40,324	37,482	38,589	40,602	42,480
Net Income (USD Mil)	16,370	13,350	14,026	26,806	23,636	24,276	26,187	27,877
Adjusted Net Income (USD Mil)	27,037	25,410	24,240	26,215	27,982	28,176	29,697	31,026
Free Cash Flow To The Firm (USD Mil)	-3,854	18,648	1,196	14,202	27,996	27,474	28,845	31,241
Weighted Average Diluted Shares Outstanding (Mil)	2,664	2,560	2,429	2,429	2,440	2,391	2,343	2,297
Earnings Per Share (Diluted) (USD)	6.15	5.21	5.77	11.03	9.69	10.15	11.18	12.14
Adjusted Earnings Per Share (Diluted) (USD)	10.15	9.92	9.98	10.79	11.47	11.78	12.67	13.51
Dividends Per Share (USD)	4.45	4.70	4.91	4.96	5.20	5.46	5.73	6.02

Margins & Returns as of 21 Jan 2026

	3 Year Avg	Actual			Forecast					5 Year Avg
		2022	2023	2024	2025	2026	2027	2028	2029	
Operating Margin %	19.7	26.3	27.5	24.9	27.2	27.8	28.4	29.1	29.6	30.9
EBITDA Margin %	—	32.7	25.9	26.4	42.8	37.4	37.3	37.3	37.3	—
Adjusted EBITDA Margin %	—	32.7	25.9	26.4	42.8	37.4	37.3	37.3	37.3	38.4
Net Margin %	17.3	20.5	15.7	15.8	28.5	23.6	23.5	24.0	24.5	29.8
Adjusted Net Margin %	30.3	33.8	29.8	27.3	27.8	27.9	27.2	27.3	27.2	27.5
Free Cash Flow To The Firm Margin %	6.1	-4.8	21.9	1.4	15.1	27.9	26.6	26.5	27.4	24.7

Growth & Ratios as of 21 Jan 2026

	3 Year CAGR	Actual			Forecast					5 Year CAGR
		2022	2023	2024	2025	2026	2027	2028	2029	
Revenue Growth %	4.1	1.6	6.5	4.3	6.1	6.4	3.2	5.3	4.7	5.1
Operating Income Growth %	1.9	0.3	11.4	-5.4	15.6	8.9	5.3	7.7	6.6	8.8
EBITDA Growth %	21.0	-2.2	-15.4	6.0	72.3	-7.0	2.9	5.2	4.6	1.6
Adjusted EBITDA Growth %	-4.3	-2.2	-15.4	6.0	72.3	-7.0	2.9	5.2	4.6	12.7
Earnings Per Share Growth %	-4.6	-7.7	-15.2	10.7	91.1	-12.2	4.8	10.1	8.6	16.0
Adjusted Earnings Per Share Growth %	-4.6	3.6	-2.2	0.5	8.2	6.3	2.8	7.6	6.6	16.0

Valuation as of 21 Jan 2026

	Actual			Forecast				
	2022	2023	2024	2025	2026	2027	2028	2029
Price/Earning	—	15.8	14.5	20.2	19.0	18.5	17.2	16.2
Price/Sales	—	4.4	3.9	5.6	5.2	5.1	4.8	4.6
Price/Book	—	5.8	4.9	6.1	5.4	5.2	4.9	4.6
Price/Cash Flow	—	—	—	—	—	—	—	—
EV/EBITDA	—	17.4	15.5	13.7	14.8	14.3	13.6	13.0
EV/EBIT	—	16.4	16.4	21.6	19.8	18.8	17.5	16.4
Dividend Yield %	—	3.0	3.4	2.3	2.4	2.5	2.6	2.8
Dividend Payout %	43.8	47.4	49.2	46.0	45.3	46.3	45.2	44.6
Free Cash Flow Yield %	—	—	—	—	—	—	—	—

Operating Performance / Profitability as of 21 Jan 2026

Fiscal Year, ends 31 Dec	Actual			Forecast				
	2022	2023	2024	2025	2026	2027	2028	2029
ROA %	8.0	7.8	12.9	10.7	11.0	11.8	12.3	12.5
ROE %	19.4	19.6	31.1	23.8	24.0	25.1	25.6	25.3
ROIC %	17.1	16.3	15.3	16.4	17.6	19.2	20.6	21.3

Johnson & Johnson JNJ ★★

21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

Financial Leverage (Reporting Currency)	Actual			Forecast				
	2022	2023	2024	2025	2026	2027	2028	2029
Fiscal Year, ends 31 Dec								
Debt/Capital %	7.9	7.2	9.5	9.6	8.9	8.4	8.0	7.5
Assets/Equity	2.2	2.4	2.5	2.4	2.2	2.2	2.1	2.1
Net Debt/EBITDA	0.7	0.3	0.5	0.2	-0.2	-0.3	-0.4	-0.6
Total Debt/EBITDA	1.5	1.3	1.6	1.2	1.2	1.1	1.0	1.0
EBITDA/ Net Interest Expense	-122.0	-45.2	-40.6	-474.4	107.1	128.6	162.4	212.4

Forecast Revisions as of 21 Jan 2026	2025		2026		2027	
	Current	Prior	Current	Prior	Current	Prior
Prior data as of 5 Jan 2026						
Fair Value Estimate Change (Trading Currency)	182.00	172.08	—	—	—	—
Revenue (USD Mil)	94,195	93,538	100,262	98,453	103,471	100,979
Operating Income (USD Mil)	25,598	25,175	27,887	27,140	29,376	28,553
EBITDA (USD Mil)	40,324	40,729	37,482	36,703	38,589	37,714
Net Income (USD Mil)	26,215	25,805	27,982	27,268	28,176	27,904
Earnings Per Share (Diluted) (USD)	11.03	10.73	9.69	9.70	10.15	10.38
Adjusted Earnings Per Share (Diluted) (USD)	10.79	10.73	11.47	11.57	11.78	12.08
Dividends Per Share (USD)	4.96	4.96	5.20	5.20	5.46	5.46

Key Valuation Drivers as of 21 Jan 2026

Cost of Equity %	7.5
Pre-Tax Cost of Debt %	5.3
Weighted Average Cost of Capital %	7.2
Long-Run Tax Rate %	19.0
Stage II EBI Growth Rate %	4.0
Stage II Investment Rate %	20.0
Perpetuity Year	20

Additional estimates and scenarios available for download at <https://pitchbook.com/>.

Discounted Cash Flow Valuation as of 21 Jan 2026

	USD Mil
Present Value Stage I	190,427
Present Value Stage II	96,696
Present Value Stage III	152,448
Total Firm Value	439,572
Cash and Equivalents	24,522
Debt	36,634
Other Adjustments	-945
Equity Value	422,197
Projected Diluted Shares	2,431
Fair Value per Share (USD)	182.00

Johnson & Johnson JNJ ★★ 21 Jan 2026 21:03, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
218.21 USD 20 Jan 2026	182.00 USD 21 Jan 2026 20:53, UTC	1.20	525.39 USD Bil 21 Jan 2026	Wide	Large Value	Low	Standard	 7 Jan 2026 06:00, UTC

ESG Risk Rating Breakdown


Exposure

Company Exposure¹	45.1
- Manageable Risk	41.5
Unmanageable Risk²	3.5

Management

Manageable Risk	41.5
- Managed Risk³	26.3
Management Gap⁴	15.3

Overall Unmanaged Risk 18.8



- Exposure represents a company's vulnerability to ESG risks driven by their business model
- Exposure is assessed at the Subindustry level and then specified at the company level
- Scoring ranges from 0-55+ with categories of low, medium, and high-risk exposure

- Management measures a company's ability to manage ESG risks through its commitments and actions
- Management assesses a company's efficiency on ESG programs, practices, and policies
- Management score ranges from 0-100% showing how much manageable risk a company is managing

ESG Risk Rating



ESG Risk Ratings measure the degree to which a company's value is impacted by environmental, social, and governance risks, by evaluating the company's ability to manage the ESG risks it faces.

1. A company's Exposure to material ESG issues 2. Unmanageable Risk refers to risks that are inherent to a particular business model that cannot be managed by programs or initiatives 3. Managed Risk = Manageable Risk multiplied by a Management score of 63.2% 4. Management Gap assesses risks that are not managed, but are considered manageable 5. ESG Risk Rating Assessment = Overall Unmanaged Risk = Management Gap plus Unmanageable Risk

ESG Risk Rating Assessment⁵



ESG Risk Rating is of Jan 07, 2026. Highest Controversy Level is as of Jan 08, 2026. Sustainalytics Subindustry: Pharmaceuticals. Sustainalytics provides Morningstar with company ESG ratings and metrics on a monthly basis and as such, the ratings in Morningstar may not necessarily reflect current Sustainalytics' scores for the company. For the most up to date rating and more information, please visit: sustainalytics.com/esg-ratings/.

Peer Analysis 07 Jan 2026

Peers are selected from the company's Sustainalytics-defined Subindustry and are displayed based on the closest market cap values

Company Name	Exposure	Management	ESG Risk Rating
Johnson & Johnson	45.1 Medium 0 —●— 55+	63.2 Strong 100 —●— 0	18.8 Low 0 —●— 40+
Eli Lilly and Co	43.9 Medium 0 —●— 55+	57.1 Strong 100 —●— 0	20.7 Medium 0 —●— 40+
Merck & Co Inc	46.4 Medium 0 —●— 55+	69.1 Strong 100 —●— 0	16.7 Low 0 —●— 40+
Procter & Gamble Co	44.5 Medium 0 —●— 55+	52.0 Strong 100 —●— 0	23.9 Medium 0 —●— 40+
Novartis AG	45.7 Medium 0 —●— 55+	82.0 Strong 100 —●— 0	10.9 Low 0 —●— 40+

Appendix

Historical Morningstar Rating

Johnson & Johnson JNJ 21 Jan 2026 20:56, UTC

Dec 2026	Nov 2026	Oct 2026	Sep 2026	Aug 2026	Jul 2026	Jun 2026	May 2026	Apr 2026	Mar 2026	Feb 2026	Jan 2026
—	—	—	—	—	—	—	—	—	—	—	★★
Dec 2025 ★★	Nov 2025 ★★	Oct 2025 ★★	Sep 2025 ★★★	Aug 2025 ★★★★	Jul 2025 ★★★★	Jun 2025 ★★★★	May 2025 ★★★★	Apr 2025 ★★★★	Mar 2025 ★★★★	Feb 2025 ★★★★	Jan 2025 ★★★★
Dec 2024 ★★★★	Nov 2024 ★★★★	Oct 2024 ★★★★	Sep 2024 ★★★★	Aug 2024 ★★★★	Jul 2024 ★★★★	Jun 2024 ★★★★	May 2024 ★★★★	Apr 2024 ★★★★	Mar 2024 ★★★★	Feb 2024 ★★★★	Jan 2024 ★★★★
Dec 2023 ★★★★	Nov 2023 ★★★★	Oct 2023 ★★★★	Sep 2023 ★★★★	Aug 2023 ★★★★	Jul 2023 ★★★★	Jun 2023 ★★★★	May 2023 ★★★★	Apr 2023 ★★★★	Mar 2023 ★★★★	Feb 2023 ★★★★	Jan 2023 ★★★★
Dec 2022 ★★	Nov 2022 ★★	Oct 2022 ★★★	Sep 2022 ★★★★	Aug 2022 ★★★★	Jul 2022 ★★	Jun 2022 ★★	May 2022 ★★	Apr 2022 ★★	Mar 2022 ★★★★	Feb 2022 ★★★★	Jan 2022 ★★★★
Dec 2021 ★★★	Nov 2021 ★★★	Oct 2021 ★★★	Sep 2021 ★★★★	Aug 2021 ★★★★	Jul 2021 ★★★★	Jun 2021 ★★	May 2021 ★★	Apr 2021 ★★★★	Mar 2021 ★★★★	Feb 2021 ★★★★	Jan 2021 ★★

AbbVie Inc ABBV 20 Jan 2026 22:55, UTC

Dec 2026	Nov 2026	Oct 2026	Sep 2026	Aug 2026	Jul 2026	Jun 2026	May 2026	Apr 2026	Mar 2026	Feb 2026	Jan 2026
—	—	—	—	—	—	—	—	—	—	—	★★
Dec 2025 ★★	Nov 2025 ★★	Oct 2025 ★★	Sep 2025 ★★	Aug 2025 ★★★★	Jul 2025 ★★★★	Jun 2025 ★★★★	May 2025 ★★★★	Apr 2025 ★★★★	Mar 2025 ★★★★	Feb 2025 ★★★★	Jan 2025 ★★★★
Dec 2024 ★★★	Nov 2024 ★★★★	Oct 2024 ★★★★	Sep 2024 ★★★★	Aug 2024 ★★★★	Jul 2024 ★★★★	Jun 2024 ★★★★	May 2024 ★★★★	Apr 2024 ★★★★	Mar 2024 ★★★★	Feb 2024 ★★★★	Jan 2024 ★★
Dec 2023 ★★	Nov 2023 ★★★★	Oct 2023 ★★★★	Sep 2023 ★★	Aug 2023 ★★	Jul 2023 ★★	Jun 2023 ★★★★	May 2023 ★★	Apr 2023 ★★	Mar 2023 ★★	Feb 2023 ★★	Jan 2023 ★★
Dec 2022 ★★	Nov 2022 ★★	Oct 2022 ★★	Sep 2022 ★★★★	Aug 2022 ★★★★	Jul 2022 ★★	Jun 2022 ★★	May 2022 ★★	Apr 2022 ★★	Mar 2022 ★	Feb 2022 ★★	Jan 2022 ★★
Dec 2021 ★★	Nov 2021 ★★★★	Oct 2021 ★★★★	Sep 2021 ★★★★	Aug 2021 ★★★★	Jul 2021 ★★★★	Jun 2021 ★★	May 2021 ★★	Apr 2021 ★★★★	Mar 2021 ★★★★	Feb 2021 ★★★★	Jan 2021 ★★★★

Merck & Co Inc MRK 20 Jan 2026 22:40, UTC

Dec 2026	Nov 2026	Oct 2026	Sep 2026	Aug 2026	Jul 2026	Jun 2026	May 2026	Apr 2026	Mar 2026	Feb 2026	Jan 2026
—	—	—	—	—	—	—	—	—	—	—	★★★★
Dec 2025 ★★★★	Nov 2025 ★★★★	Oct 2025 ★★★★	Sep 2025 ★★★★	Aug 2025 ★★★★	Jul 2025 ★★★★	Jun 2025 ★★★★	May 2025 ★★★★★	Apr 2025 ★★★★	Mar 2025 ★★★★	Feb 2025 ★★★★	Jan 2025 ★★★★
Dec 2024 ★★★★	Nov 2024 ★★★★	Oct 2024 ★★★★	Sep 2024 ★★★★	Aug 2024 ★★★★	Jul 2024 ★★★★	Jun 2024 ★★★★	May 2024 ★★★★	Apr 2024 ★★★★	Mar 2024 ★★	Feb 2024 ★★	Jan 2024 ★★
Dec 2023 ★★★★	Nov 2023 ★★★★	Oct 2023 ★★★★	Sep 2023 ★★★★	Aug 2023 ★★	Jul 2023 ★★	Jun 2023 ★★	May 2023 ★★	Apr 2023 ★★	Mar 2023 ★★	Feb 2023 ★★	Jan 2023 ★★
Dec 2022 ★★	Nov 2022 ★★	Oct 2022 ★★★★	Sep 2022 ★★★★	Aug 2022 ★★★★	Jul 2022 ★★★★	Jun 2022 ★★★★	May 2022 ★★★★	Apr 2022 ★★★★	Mar 2022 ★★★★	Feb 2022 ★★★★	Jan 2022 ★★★★
Dec 2021 ★★★★	Nov 2021 ★★★★	Oct 2021 ★★★★	Sep 2021 ★★★★	Aug 2021 ★★★★	Jul 2021 ★★★★	Jun 2021 ★★★★	May 2021 ★★★★	Apr 2021 ★★★★	Mar 2021 ★★★★	Feb 2021 ★★★★	Jan 2021 ★★★★

Novartis AG Registered Shares NOVN 21 Jan 2026 18:21, UTC

Dec 2026 —	Nov 2026 —	Oct 2026 —	Sep 2026 —	Aug 2026 —	Jul 2026 —	Jun 2026 —	May 2026 —	Apr 2026 —	Mar 2026 —	Feb 2026 —	Jan 2026 ★★
Dec 2025 —	Nov 2025 ★★★	Oct 2025 ★★★	Sep 2025 ★★	Aug 2025 ★★	Jul 2025 ★★	Jun 2025 ★★	May 2025 ★★	Apr 2025 ★★	Mar 2025 ★★★	Feb 2025 ★★★	Jan 2025 ★★★
Dec 2024 —	Nov 2024 ★★★	Oct 2024 ★★★	Sep 2024 ★★★	Aug 2024 ★★★	Jul 2024 ★★★	Jun 2024 ★★★	May 2024 ★★★	Apr 2024 ★★★	Mar 2024 ★★★	Feb 2024 ★★★	Jan 2024 ★★★
Dec 2023 ★★★	Nov 2023 ★★★	Oct 2023 ★★★	Sep 2023 ★★★	Aug 2023 ★★★	Jul 2023 ★★★	Jun 2023 ★★★	May 2023 ★★★	Apr 2023 ★★	Mar 2023 ★★★★	Feb 2023 ★★★★	Jan 2023 ★★★
Dec 2022 ★★★	Nov 2022 ★★★★	Oct 2022 ★★★★	Sep 2022 ★★★★	Aug 2022 ★★★★	Jul 2022 ★★★★	Jun 2022 ★★★★	May 2022 ★★★	Apr 2022 ★★★	Mar 2022 ★★★	Feb 2022 ★★★	Jan 2022 ★★★
Dec 2021 —	Nov 2021 ★★★★	Oct 2021 ★★★★	Sep 2021 ★★★★	Aug 2021 ★★★	Jul 2021 ★★★	Jun 2021 ★★★	May 2021 ★★★	Apr 2021 ★★★	Mar 2021 ★★★	Feb 2021 ★★★	Jan 2021 ★★★

Research Methodology for Valuing Companies

Overview

At the heart of our valuation system is a detailed projection of a company's future cash flows, resulting from our analysts' research. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into our globally standardized, proprietary discounted cash flow, or DCF, modeling templates. We use scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools to augment this process. Moreover, we think analyzing valuation through discounted cash flows presents a better lens for viewing cyclical companies, high-growth firms, businesses with finite lives (e.g., mines), or companies expected to generate negative earnings over the next few years. That said, we don't dismiss multiples altogether but rather use them as supporting cross-checks for our DCF-based fair value estimates. We also acknowledge that DCF models offer their own challenges (including a potential proliferation of estimated inputs and the possibility that the method may miss short-term market-price movements), but we believe these negatives are mitigated by deep analysis and our long-term approach.

Morningstar's equity research group ("we," "our") believes that a company's intrinsic worth results from the future cash flows it can generate. The Morningstar Rating for stocks identifies stocks trading at a discount or premium to their intrinsic worth—or fair value estimate, in Morningstar terminology. Five-star stocks sell for the biggest risk adjusted discount to their fair values, whereas 1-star stocks trade at premiums to their intrinsic worth.

Four key components drive the Morningstar rating: (1) our assessment of the firm's economic moat, (2) our estimate of the stock's fair value, (3) our uncertainty around that fair value estimate and (4) the current market price. This process ultimately culminates in our single-point star rating.

1. Economic Moat

The concept of an economic moat plays a vital role not only in our qualitative assessment of a firm's long-term investment potential, but also in the actual calculation of our fair value estimates. An economic moat is a structural feature that allows a firm to sustain excess profits over a

long period of time. We define economic profits as returns on invested capital (or ROIC) over and above our estimate of a firm's cost of capital, or weighted average cost of capital (or WACC). Without a moat, profits are more susceptible to competition. We have identified five sources of economic moats: intangible assets, switching costs, network effect, cost advantage, and efficient scale.

Companies with a narrow moat are those we believe are more likely than not to achieve normalized excess returns for at least the next 10 years. Wide-moat companies are those in which we have very high confidence that excess returns will remain for 10 years, with excess returns more likely than not to remain for at least 20 years. The longer a firm generates economic profits, the higher its intrinsic value. We believe low-quality, no-moat companies will see their normalized returns gravitate toward the firm's cost of capital more quickly than companies with moats.

When considering a company's moat, we also assess whether there is a substantial threat of value destruction, stemming from risks related to ESG, industry disruption, financial health, or other idiosyncratic issues. In this context, a risk is considered potentially value destructive if its occurrence would eliminate a firm's economic profit on a cumulative or midcycle basis. If we deem the probability of occurrence sufficiently high, we would not characterize the company as possessing an economic moat.

2. Estimated Fair Value

Combining our analysts' financial forecasts with the firm's economic moat helps us assess how long returns on invested capital are likely to exceed the firm's cost of capital. Returns of firms with a wide economic moat rating are assumed to fade to the perpetuity period over a longer period of time than the returns of narrow-moat firms, and both will fade slower than no-moat firms, increasing our estimate of their intrinsic value.

Our model is divided into three distinct stages:

Stage I: Explicit Forecast

In this stage, which can last five to 10 years, analysts make full financial statement forecasts, including items such as revenue, profit margins, tax rates, changes in working capital accounts, and capital spending. Based on these projections, we calculate earnings before interest,

after taxes (EBI) and the net new investment (NNI) to derive our annual free cash flow forecast.

Stage II: Fade

The second stage of our model is the period it will take the company's return on new invested capital—the return on capital of the next dollar invested ("RONIC")—to decline (or rise) to its cost of capital. During the Stage II period, we use a formula to approximate cash flows in lieu of explicitly modeling the income statement, balance sheet, and cash flow statement as we do in Stage I. The length of the second stage depends on the strength of the company's economic moat. We forecast this period to last anywhere from one year (for companies with no economic moat) to 10–15 years or more (for wide-moat companies). During this period, cash flows are forecast using four assumptions: an average growth rate for EBI over the period, a normalized investment rate, average return on new invested capital (RONIC), and the number of years until perpetuity, when excess returns cease. The investment rate and return on new invested capital decline until a perpetuity value is calculated. In the case of firms that do not earn their cost of capital, we assume marginal ROICs rise to the firm's cost of capital (usually attributable to less reinvestment), and we may truncate the second stage.

Stage III: Perpetuity

Once a company's marginal ROIC hits its cost of capital, we calculate a continuing value, using a standard perpetuity formula. At perpetuity, we assume that any growth or decline or investment in the business neither creates nor destroys value and that any new investment provides a return in line with estimated WACC.

Because a dollar earned today is worth more than a dollar earned tomorrow, we discount our projections of cash flows in stages I, II, and III to arrive at a total present value of expected future cash flows. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the WACC, which is a weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

3. Uncertainty Around That Fair Value Estimate

Morningstar's Uncertainty Rating is designed to capture the range of potential outcomes for a company's intrinsic value. This rating is used to assign the margin of safety required before investing, which in turn explicitly drives our stock star rating system. The Uncertainty Rating is aimed at identifying the confidence we should have in assigning a fair value estimate for a given stock.

Our Uncertainty Rating is meant to take into account anything that can increase the potential dispersion of future

Morningstar Equity Research Star Rating Methodology



Research Methodology for Valuing Companies

outcomes for the intrinsic value of a company, and anything that can affect our ability to accurately predict these outcomes. The rating begins with a suggested rating produced by a quantitative process based on the trailing 12-month standard deviation of daily stock returns. An analyst overlay is then applied, with analysts using the suggested rating, historical rating data, and their own knowledge of the company to inform them as they make the final Uncertainty Rating decision. Ultimately, the rating decision rests with the analyst. Analysts take into account many characteristics when making their final decision, including cyclical factors, operational and financial factors such as leverage, company-specific events, ESG risks, and anything else that might increase the potential dispersion of future outcomes and our ability to estimate those outcomes.

Our recommended margin of safety—the discount to fair value demanded before we'd recommend buying or selling the stock—widens as our uncertainty of the estimated value of the equity increases. The more uncertain we are about the potential dispersion of outcomes, the greater the discount we require relative to our estimate of the value of the firm before we would recommend the purchase of the shares. In addition, the Uncertainty Rating provides guidance in portfolio construction based on risk tolerance.

Our Uncertainty Ratings are: Low, Medium, High, Very High, and Extreme.

Margin of Safety		
Qualitative Analysis	★★★★★ Rating	★ Rating
Uncertainty Ratings		
Low	20% Discount	25% Premium
Medium	30% Discount	35% Premium
High	40% Discount	55% Premium
Very High	50% Discount	75% Premium
Extreme	75% Discount	300% Premium


Our uncertainty rating is based on the interquartile range, or the middle 50% of potential outcomes, covering the 25th percentile–75th percentile. This means that when a stock hits 5 stars, we expect there is a 75% chance that the intrinsic value of that stock lies above the current market price. Similarly, when a stock hits 1 star, we expect there is a 75% chance that the intrinsic value of that stock lies below the current market price.

4. Market Price

The market prices used in this analysis and noted in the report come from exchange on which the stock is listed which we believe is a reliable source.

For more details about our methodology, please go to <https://shareholders.morningstar.com>

Morningstar Equity Research Star Rating Methodology



Morningstar Star Rating for Stocks

Once we determine the fair value estimate of a stock, we compare it with the stock's current market price on a daily basis, and the star rating is automatically re-calculated at the market close on every day the market on which the stock is listed is open. Our analysts keep close tabs on the companies they follow, and, based on thorough and ongoing analysis, raise or lower their fair value estimates as warranted.

Please note, there is no predefined distribution of stars. That is, the percentage of stocks that earn 5 stars can fluctuate daily, so the star ratings, in the aggregate, can serve as a gauge of the broader market's valuation. When there are many 5-star stocks, the stock market as a whole is more undervalued, in our opinion, than when very few companies garner our highest rating.

We expect that if our base-case assumptions are true the market price will converge on our fair value estimate over time generally within three years (although it is impossible to predict the exact time frame in which market prices may adjust).

Our star ratings are guideposts to a broad audience and individuals must consider their own specific investment goals, risk tolerance, tax situation, time horizon, income needs, and complete investment portfolio, among other factors.

The Morningstar Star Ratings for stocks are defined below:

★★★★★ We believe appreciation beyond a fair risk-adjusted return is highly likely over a multiyear time frame. Scenario analysis developed by our analysts indicates that the current market price represents an excessively pessimistic outlook, limiting downside risk and maximizing upside potential.

★★★★ We believe appreciation beyond a fair risk-adjusted return is likely.

★★★ Indicates our belief that investors are likely to receive a fair risk-adjusted return (approximately cost of equity).

★★ We believe investors are likely to receive a less than fair risk-adjusted return.

★ Indicates a high probability of undesirable risk-adjusted returns from the current market price over a multi-year time frame, based on our analysis. Scenario analysis by our analysts indicates that the market is pricing in an excessively optimistic outlook, limiting upside potential and leaving the investor exposed to Capital loss.

Other Definitions

Last Price: Price of the stock as of the close of the market of the last trading day before date of the report.

Capital Allocation Rating: Our Capital Allocation (or Stewardship) Rating represents our assessment of the quality of management's capital allocation, with particular emphasis on the firm's balance sheet, investments,

Research Methodology for Valuing Companies

and shareholder distributions. Analysts consider companies' investment strategy and valuation, balance sheet management, and dividend and share buyback policies. Corporate governance factors are only considered if they are likely to materially impact shareholder value, though either the balance sheet, investment, or shareholder distributions. Analysts assign one of three ratings: "Exemplary", "Standard", or "Poor". Analysts judge Capital Allocation from an equity holder's perspective. Ratings are determined on a forward looking and absolute basis. The Standard rating is most common as most managers will exhibit neither exceptionally strong nor poor capital allocation.

Capital Allocation (or Stewardship) analysis published prior to Dec. 9, 2020, was determined using a different process. Beyond investment strategy, financial leverage, and dividend and share buyback policies, analysts also considered execution, compensation, related party transactions, and accounting practices in the rating.

Capital Allocation Rating: Our Capital Allocation (or Stewardship) Rating represents our assessment of the quality of management's capital allocation, with particular emphasis on the firm's balance sheet, investments, and shareholder distributions. Analysts consider companies' investment strategy and valuation, balance sheet management, and dividend and share buyback policies. Corporate governance factors are only considered if they are likely to materially impact shareholder value, though either the balance sheet, investment, or shareholder distributions. Analysts assign one of three ratings: "Exemplary", "Standard", or "Poor". Analysts judge Capital Allocation from an equity holder's perspective. Ratings are determined on a forward looking and absolute basis. The Standard rating is most common as most managers will exhibit neither exceptionally strong nor poor capital allocation.

Capital Allocation (or Stewardship) analysis published prior to Dec. 9, 2020, was determined using a different process. Beyond investment strategy, financial leverage, and dividend and share buyback policies, analysts also considered execution, compensation, related party transactions, and accounting practices in the rating.

Sustainalytics ESG Risk Rating Assessment: The ESG Risk Rating Assessment is provided by Sustainalytics; a Morningstar company.

Sustainalytics' ESG Risk Ratings measure the degree to which company's economic value at risk is driven by environment, social and governance (ESG) factors.

Sustainalytics analyzes over 1,300 data points to assess a company's exposure to and management of ESG risks. In other words, ESG Risk Ratings measures a company's unmanaged ESG Risks represented as a quantitative score.

Unmanaged Risk is measured on an open-ended scale starting at zero (no risk) with lower scores representing less unmanaged risk and, for 95% of cases, the unmanaged ESG Risk score is below 50.

Based on their quantitative scores, companies are grouped into one of five Risk Categories (negligible, low, medium, high, severe). These risk categories are absolute, meaning that a 'high risk' assessment reflects a comparable degree of unmanaged ESG risk across all subindustries covered.

The ESG Risk Rating Assessment is a visual representation of Sustainalytics ESG Risk Categories on a 1 to 5 scale. Companies with Negligible Risk = 5 Globes, Low Risk = 4, Medium Risk = 3 Globes, High Risk = 2 Globes, Severe Risk = 1 Globe. For more information, please visit sustainalytics.com/esg-ratings/

Ratings should not be used as the sole basis in evaluating a company or security. Ratings involve unknown risks and uncertainties which may cause our expectations not to occur or to differ significantly from what was expected and should not be considered an offer or solicitation to buy or sell a security.

Risk Warning

Please note that investments in securities are subject to market and other risks and there is no assurance or guarantee that the intended investment objectives will be achieved. Past performance of a security may or may not be sustained in future and is no indication of future performance. A security investment return and an investor's principal value will fluctuate so that, when redeemed, an investor's shares may be worth more or less than their original cost. A security's current investment performance may be lower or higher than the investment performance noted within the report. Morningstar's Uncertainty Rating serves as a useful data point with respect to sensitivity analysis of the assumptions used in our determining a fair value price.

General Disclosure

Unless otherwise provided in a separate agreement, recipients accessing this report may only use it in the country in which the Morningstar distributor is based. Unless stated otherwise, the original distributor of the report is Morningstar Research Services LLC, a U.S.A. domiciled financial institution.

This Report is for informational purposes, should not be the sole piece of information used in making an investment decision, and has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. This publication is intended to provide information to assist investors in making their

own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed herein may not be suitable for all investors; investors must exercise their own independent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position. Morningstar encourages Report recipients to read all relevant issue documents (e.g., prospectus) pertaining to the security concerned, including without limitation, information relevant to its investment objectives, risks, and costs before making an investment decision and when deemed necessary, to seek the advice of a financial, legal, tax, and/or accounting professional. The information, data, analyses and opinions presented herein are not warranted to be accurate, correct, complete or timely. Unless otherwise provided in a separate agreement, neither Morningstar, Inc. or the Equity Research Group represents that the report contents meet all of the presentation and/or disclosure standards applicable in the jurisdiction the recipient is located.

Except as otherwise required by law or provided for in a separate agreement, the analyst, Morningstar, Inc. and the Equity Research Group and their officers, directors and employees shall not be responsible or liable for any trading decisions, damages or other losses resulting from, or related to, the information, data, analyses or opinions within the report.

The Report and its contents are not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Morningstar, Inc. or its affiliates to any registration or licensing requirements in such jurisdiction.

Where this report is made available in a language other than English and in the case of inconsistencies between the English and translated versions of the report, the English version will control and supersede any ambiguities associated with any part or section of a report that has been issued in a foreign language. Neither the analyst, Morningstar, Inc., or the Equity Research Group guarantees the accuracy of the translations.

This report may be distributed in certain localities, countries and/or jurisdictions ("Territories") by independent third parties or independent intermediaries and/or distributors ("Distributors"). Such Distributors are not acting as agents or representatives of the analyst, Morningstar, Inc. or the Equity Research Group. In Territories where a Distributor distributes our report, the Distributor is solely responsible for complying with all applicable regulations, laws, rules, circulars, codes and guidelines established

Research Methodology for Valuing Companies

by local and/or regional regulatory bodies, including laws in connection with the distribution third-party research reports.

Conflicts of Interest

- ▶ No interests are held by the analyst with respect to the security subject of this investment research report.
- ▶ Morningstar, Inc. may hold a long position in the security subject of this investment research report that exceeds 0.5% of the total issued share capital of the security. To determine if such is the case, please click <http://msi.morningstar.com> and <http://mdi.morningstar.com>
- ▶ Analysts' compensation is derived from Morningstar, Inc.'s overall earnings and consists of salary, bonus and in some cases restricted stock.
- ▶ Neither Morningstar, Inc. or the Equity Research Group receives commissions for providing research nor do they charge companies to be rated.
- ▶ Morningstar's overall earnings are generated in part by the activities of the Investment Management and Research groups, and other affiliates, who provide services to product issuers.
- ▶ Morningstar employees may not pursue business and employment opportunities outside Morningstar within the investment industry (including but not limited to, working as a financial planner, an investment professional or investment professional representative, a broker-dealer or broker-dealer agent, a financial writer, reporter, or analyst) without the approval of Morningstar's Legal and if applicable, Compliance teams.
- ▶ Neither Morningstar, Inc. or the Equity Research Group is a market maker or a liquidity provider of the security noted within this report.
- ▶ Neither Morningstar, Inc. or the Equity Research Group has been a lead manager or co-lead manager over the previous 12-months of any publicly disclosed offer of financial instruments of the issuer.
- ▶ Morningstar, Inc.'s investment management group does have arrangements with financial institutions to provide portfolio management/investment advice some of which an analyst may issue investment research reports on. However, analysts do not have authority over Morningstar's investment management group's business arrangements nor allow employees from the investment management group to participate or influence the analysis or opinion prepared by them.
- ▶ Morningstar, Inc. is a publicly traded company (Ticker Symbol: MORN) and thus a financial institution the security of which is the subject of this report may own more than 5% of Morningstar, Inc.'s total outstanding shares. Please access Morningstar, Inc.'s proxy statement, "Security Ownership of Certain Beneficial Owners and Management" section <https://shareholders.morningstar.com/investor-relations/financials/sec-filings/default.aspx>

- ▶ Morningstar, Inc. may provide the product issuer or its related entities with services or products for a fee and on an arms' length basis including software products and licenses, research and consulting services, data services, licenses to republish our ratings and research in their promotional material, event sponsorship and website advertising.

Further information on Morningstar, Inc.'s conflict of interest policies is available from <http://global.morningstar.com/equitydisclosures>. Also, please note analysts are subject to the CFA Institute's Code of Ethics and Standards of Professional Conduct.

Risk Warning Please note that investments in securities are subject to market and other risks and there is no assurance or guarantee that the intended investment objectives will be achieved. Past performance of a security may or may not be sustained in future and is no indication of future performance. A security's investment return and an investor's principal value will fluctuate so that, when redeemed, an investor's shares may be worth more or less than their original cost. A security's current investment performance may be lower or higher than the investment performance noted within the report. For investments in foreign markets there are further risks, generally based on exchange rate changes or changes in political and social conditions.

For more information about Morningstar's methodologies, please visit global.morningstar.com/equitydisclosures

For a list of securities which the Equity Research Group currently covers and provides written analysis on please contact your local Morningstar office. In addition, for historical analysis of securities covered, including their fair value estimate, please contact your local office.

For recipients in Australia: This Report has been issued and distributed in Australia by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544; ASFL: 240892). Morningstar Australasia Pty Ltd is the provider of the general advice ('the Service') and takes responsibility for the production of this report. The Service is provided through the research of investment products.

To the extent the Report contains general advice it has been prepared without reference to an investor's objectives, financial situation or needs. Investors should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement before making any decision to invest. Refer to our Financial Services Guide (FSG) for more information at <http://www.morningstar.com.au/fsg.pdf>

For recipients in New Zealand: This report has been is-

sued and distributed by Morningstar Australasia Pty Ltd and/or Morningstar Research Ltd (together 'Morningstar'). This report has been prepared and is intended for distribution in New Zealand to wholesale clients only and has not been prepared for use by New Zealand retail clients (as those terms are defined in the Financial Markets Conduct Act 2013). The information, views and any recommendations in this material are provided for general information purposes only, and solely relate to the companies and investment opportunities specified within. Our reports do not take into account any particular investor's financial situation, objectives or appetite for risk, meaning no representation may be implied as to the suitability of any financial product mentioned for any particular investor. We recommend seeking financial advice before making any investment decision.

For recipients in Hong Kong: The Report is distributed by Morningstar Investment Management Asia Limited, which is regulated by the Hong Kong Securities and Futures Commission to provide services to professional investors only. Neither Morningstar Investment Management Asia Limited, nor its representatives, are acting or will be deemed to be acting as an investment professional to any recipients of this information unless expressly agreed to by Morningstar Investment Management Asia Limited.

For recipients in India: This investment research is issued by Morningstar Investment Adviser India Private Limited. Morningstar Investment Adviser India Private Limited is registered with SEBI as a Portfolio Manager (registration number INP000006156) and as a Research Entity (registration number INH000008686). Morningstar Investment Adviser India Private Limited has not been the subject of any disciplinary action by SEBI or any other legal/regulatory body. Morningstar Investment Adviser India Private Limited is a wholly owned subsidiary of Morningstar Investment Management LLC. In India, Morningstar Investment Adviser India Private Limited has one associate, Morningstar India Private Limited, which provides data-related services, financial data analysis, and software development. The research analyst has not served as an officer, director, or employee of the fund company within the last 12 months, nor have they or their associates engaged in market-making activity for the fund company. The ESG-related information, methodologies, tool, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.

*The Conflicts of Interest disclosure above also applies to relatives and associates of Manager Research Analysts in

Research Methodology for Valuing Companies

India # The Conflicts of Interest disclosure above also applies to associates of Manager Research Analysts in India. The terms and conditions on which Morningstar Investment Adviser India Private Limited offers Investment Research to clients, varies from client to client, and are detailed in the respective client agreement.

For recipients in Japan: The Report is distributed by Ibbotson Associates Japan, Inc., which is regulated by Financial Services Agency, for informational purposes only. Neither Ibbotson Associates Japan, Inc., nor its representatives, are acting or will be deemed to be acting as an investment professional to any recipients of this information.

For recipients in Singapore: The Report is intended for Institutional Investor audiences and is distributed by Morningstar Investment Adviser Singapore Pte. Limited, which is licensed by the Monetary Authority of Singapore to provide financial advisory services in Singapore. Morningstar Investment Adviser Singapore Pte. Limited is the entity responsible for the creation and distribution of the research services described in this Report.

This content is provided for informational purposes only and may be shared or redistributed by Institutional Investors to their clients or other permitted persons, subject to obtaining the appropriate licence from Morningstar. Redistribution of this content is subject to any applicable conditions or limitations, including those agreed commercially or contractually with Morningstar. The person who shares or redistributes this content shall be solely responsible for compliance with all relevant legal and regulatory obligations in the jurisdictions in which the material is made available.

Investors should consult a financial adviser regarding the suitability of any investment product, taking into account their specific investment objectives, financial situation or particular needs, before making any investment decision.

Morningstar, Inc., and its affiliates rely on certain exemptions (Financial Advisers Regulations, Section 27(1)(e), Section 32B and 32C) to provide its investment research to recipients in Singapore.

For recipients in Korea: The report is distributed by Morningstar Korea Ltd., which has filed to the Financial Services Committee, for informational purposes only. Neither Morningstar Korea Ltd. nor its representatives are acting or will be deemed to be acting as an investment advisor to any recipients of this information.